Hypertension

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by ClueBot NG (talk | contribs) at 13:15, 8 March 2012 (Reverting possible vandalism by 200.29.103.107 to version by Luckas-bot. False positive? Report it. Thanks, ClueBot NG. (941256) (Bot)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article is about arterial hypertension. For other forms of hypertension, see Hypertension (disambiguation).
Hypertension
SpecialtyFamily medicine, hypertensiology Edit this on Wikidata

Hypertension (HTN) or high blood pressure, sometimes arterial hypertension, is a chronic medical condition in which the blood pressure in the arteries is elevated. This requires the heart to work harder than normal to circulate blood through the blood vessels. Blood pressure involves two measurements, systolic and diastolic, which depend on whether the heart muscle is contracting (systole) or relaxed (diastole) between beats. Normal blood pressure is within the range of 100-140mmHg systolic (top reading) and 60-90mmHg diastolic (bottom reading). High blood pressure is said to be present if it is persistently at or above 140/90 mmHg.

Hypertension is classified as either primary (essential) hypertension or secondary hypertension; about 90–95% of cases are categorized as "primary hypertension" which means high blood pressure with no obvious underlying medical cause.[1] The remaining 5–10% of cases (secondary hypertension) are caused by other conditions that affect the kidneys, arteries, heart or endocrine system.

Hypertension is a major risk factor for stroke, myocardial infarction (heart attacks), heart failure, aneurysms of the arteries (e.g. aortic aneurysm), peripheral arterial disease and is a cause of chronic kidney disease. Even moderate elevation of arterial blood pressure is associated with a shortened life expectancy. Dietary and lifestyle changes can improve blood pressure control and decrease the risk of associated health complications, although drug treatment is often necessary in patients for whom lifestyle changes prove ineffective or insufficient.

Classification

Classification (JNC7)[2] Systolic pressure Diastolic pressure
mmHg kPa mmHg kPa
Normal 90–119 12–15.9 60–79 8.0–10.5
Prehypertension 120–139 16.0–18.5 80–89 10.7–11.9
Stage 1 hypertension 140–159 18.7–21.2 90–99 12.0–13.2
Stage 2 hypertension ≥160 ≥21.3 ≥100 ≥13.3
Isolated systolic
hypertension 		≥140 ≥18.7 <90 <12.0

Adults

In people aged 18 years or older hypertension is defined as a systolic and/or a diastolic blood pressure measurement consistently higher than an accepted normal value (currently 139 mmHg systolic, 89 mmHg diastolic: see table — Classification (JNC7)). Lower thresholds are used (135 mmHg systolic or 85 mmHg diastolic) if measurements are derived from 24-hour ambulatory or home monitoring.[3] The presence of other cardiovascular risk factors is taken into account when decisions are made regarding drug treatment. Recent international hypertension guidelines have also created categories below the hypertensive range to indicate a continuum of risk with higher blood pressures in the normal range. JNC7 (2003)[2] uses the term prehypertension for blood pressure in the range 120-139 mmHg systolic and/or 80-89 mmHg diastolic, while ESH-ESC Guidelines (2007)[4] and BHS IV (2004)[5] use optimal, normal and high normal categories to subdivide pressures below 140 mmHg systolic and 90 mmHg diastolic. Hypertension is also sub-classified: JNC7 distinguishes hypertension stage I, hypertension stage II, and isolated systolic hypertension. Isolated systolic hypertension refers to elevated systolic pressure with normal diastolic pressure and is common in the elderly.[2] The ESH-ESC Guidelines (2007)[4] and BHS IV (2004),[5] additionally define a third stage (stage III hypertension) for people with systolic blood pressure exceeding 179 mmHg or a diastolic pressure over 109 mmHg. Hypertension is classified as "resistant" if medications do not reduce blood pressure to normal levels.[2]

Neonates and infants

Hypertension in neonates is rare, occurring in around 0.2 to 3% of neonates, and blood pressure is not measured routinely in the healthy newborn.[6] Hypertension can be more common in high risk newborns. A variety of factors, such as gestational age, postconceptional age and birth weight needs to be taken into account when deciding if a blood pressure is normal in a neonate.[6]

Children and adolescents

Hypertension occurs quite commonly in children and adolescents (2-9% depending on age, sex and ethnicity)[7] and is associated with long term risks of ill-heath.[8] It is now recommended that children over the age of 3 have their blood pressure checked whenever they attend for routine medical care or checks, but high blood pressure must be confirmed on repeated visits before characterizing a child as having hypertension.[8] Blood pressure rises with age in childhood and, in children, hypertension is defined as an average systolic or diastolic blood pressure on three or more occasions equal or higher than the 95th percentile appropriate for the sex, age and height of the child. Prehypertension in children is defined as average systolic or diastolic blood pressure that is greater than or equal to the 90th percentile, but less than the 95th percentile.[8] In adolescents, it has been proposed that hypertension and pre-hypertension are diagnosed and classified using the same criteria as in adults.[8]

Signs and symptoms

Hypertension is rarely accompanied by any symptoms, and its identification is usually through screening, or when seeking healthcare for an unrelated problem. A proportion of people with high blood pressure reports headaches (particularly at the back of the head and in the morning), as well as lightheadedness, vertigo, tinnitus (buzzing or hissing in the ears), altered vision or fainting episodes.[9]

On physical examination, hypertension may be suspected on the basis of the presence of hypertensive retinopathy detected by examination of the optic fundi using ophthalmoscopy[10] Classically, the severity of the hypertensive retinopathy changes is graded from grade I–IV, although the milder types may be difficult to distinguish from each other.[10] Ophthalmoscopy findings may also indicate how long a person has been hypertensive.[9]

Secondary hypertension

Main article: Secondary hypertension

Some additional signs and symptoms may suggest secondary hypertension, i.e. hypertension due to some identifiable cause such as kidney diseases or endocrine diseases. For example, truncal obesity, glucose intolerance, moon facies, a "buffalo hump" and purple striae suggest Cushing's syndrome.[11] Thyroid disease and acromegaly can also cause hypertension and have characteristic symptoms and signs.[11] An abdominal bruit may be an indicator of renal artery stenosis, while decreased blood pressure in the lower extremities and/or delayed or absent femoral arterial pulses may indicate aortic coarctation. Labile or paroxysmal hypertension accompanied by headache, palpitations, pallor, and perspiration should prompt suspicions of pheochromocytoma.[11]

Hypertensive crises

Main article: hypertensive emergency

Severely elevated blood pressure (systolic over 180 or diastolic over 110 — sometime termed malignant or accelerated hypertension) is referred to as a "hypertensive crisis", as blood pressures above these levels are known to confer a high risk of complications. People with blood pressures in this range may have no symptoms, but are more likely to report headaches and dizziness.[9] Other symptoms accompanying a hypertensive crisis may include visual deterioration or breathlessness due to heart failure or a general feeling of malaise due to renal failure.[11] Most people with a hypertensive crisis are known to have elevated blood pressure, but additional triggers may have led to a sudden rise.[12]

A "hypertensive emergency", previously "malignant hypertension", is diagnosed when there is evidence of direct damage to one or more organs as a result of the severely elevated blood pressure. This may include hypertensive encephalopathy, caused by brain swelling and dysfunction, and characterized by headaches and an altered level of consciousness (confusion or drowsiness). Retinal papilloedema and/or fundal hemorrhages and exudates are another sign of target organ damage. Chest pain may indicate heart muscle damage (which may progress to myocardial infarction) or sometimes aortic dissection, the tearing of the inner wall of the aorta. Breathlessness, cough, and the expectoration of blood-stained sputum are characteristic signs of pulmonary edema, the swelling of lung tissue due to left ventricular failure an inability of the left ventricle of the heart to adequately pump blood from the lungs into the arterial system.[12] Rapid deterioration of kidney function (acute kidney injury) and microangiopathic hemolytic anemia (destruction of blood cells) may also occur.[12] In these situations, rapid reduction of the blood pressure is mandated to stop ongoing organ damage.[12] In contrast there is no evidence that blood pressure needs to be lowered rapidly in hypertensive urgencies where there is no evidence of target organ damage and over aggressive reduction of blood pressure is not without risks[11] Use of oral medications to lower the BP gradually over 24 to 48 h is advocated in hypertensive urgencies.[12]

In pregnancy

Hypertension occurs in approximately 8-10% of pregnancies.[11] Most women with hypertension in pregnancy have pre-existing primary hypertension, but high blood pressure in pregnancy may be the first sign of pre-eclampsia, a serious condition of the second half of pregnancy and puerperium.[11] Pre-eclampsia is characterised by increased blood pressure and the presence of protein in the urine.[11] It occurs in about 5% of pregnancies and is responsible for approximately 16% of all maternal deaths.[11] Pre-eclampsia also doubles the risk of perinatal mortality.[11] Usually there are no symptoms in pre-eclampsia and it is detected by routine screening. When symptoms of pre-eclampsia occur the most common are headache, visual disturbance (often "flashing lights"), vomiting, epigastric pain, and edema. Pre-eclampsia can occasionally progress to a life-threatening condition called eclampsia, which is a hypertensive emergency and has several serious complications including vision loss, cerebral edema, seizures or convulsions, renal failure, pulmonary edema, and disseminated intravascular coagulation.[11][13]

In neonates, infants and children

Failure to thrive, seizures, irritability, lack of energy, and difficulty breathing[14] can be associated with hypertension in neonates and young infants. In older infants and children, hypertension can cause headache, unexplained irritability, fatigue, failure to thrive, blurred vision, nosebleeds, and facial paralysis.[6][14]

Complications

Main article: Complications of hypertension
Diagram illustrating the main complications of persistent high blood pressure.

Hypertension is the most important preventable risk factor for premature death worldwide.[15] It increases the risk of ischemic heart disease[16] strokes,[11] peripheral vascular disease,[17] and other cardiovascular diseases, including heart failure, aortic aneurysm, diffuse atherosclerosis, and pulmonary embolism.[11][11] Hypertension is also a risk factor for cognitive impairment and dementia, and chronic kidney disease.[11] Other complications include:

  • Hypertensive retinopathy
  • Hypertensive nephropathy[18]
  • Silent stroke is a type of stroke (infarct) that does not have any outward symptoms (asymptomatic), and the patient is typically unaware they have suffered a stroke. Despite not causing identifiable symptoms a silent stroke still causes damage to the brain, and places the patient at increased risk for a major stroke in the future. Hypertension is the major treatable risk factor associated with silent strokes.[19]

Cause

Primary hypertension

Main article: Essential hypertension

Primary (essential) hypertension is the most common form of hypertension, accounting for 90–95% of all cases of hypertension.[1] In almost all contemporary societies, blood pressure rises with aging and the risk of becoming hypertensive in later life is considerable.[20] Hypertension results from a complex interaction of genes and environmental factors. Numerous common genes with small effects on blood pressure have been identified[21] as well as some rare genes with large effects on blood pressure[22] but the genetic basis of hypertension is still poorly understood. Several environmental factors influence blood pressure. Lifestyle factors that lower blood pressure, include reduced dietary salt intake,[23] increased consumption of fruits and low fat products (Dietary Approaches to Stop Hypertension (DASH diet)), exercise,[24] weight loss[25] reduced alcohol intake,.[26] The possible role of other factors such as stress,[24] caffeine consumption,[27] and vitamin D deficiency[28] are less clear cut. Insulin resistance, which is common in obesity and is a component of syndrome X (or the metabolic syndrome), is also thought to contribute to hypertension.[29] Recent studies have also implicated events in early life (for example low birth weight, maternal smoking and lack of breast feeding) as risk factors for adult essential hypertension,[30] although the mechanisms linking these exposures to adult hypertension remain obscure.[30]

Secondary hypertension

Main article: Secondary hypertension

Secondary hypertension results from an identifiable cause. Renal disease is the most common secondary cause of hypertension.[11] Hypertension can also be caused by endocrine conditions, such as Cushing's syndrome, hyperthyroidism, hypothyroidism, acromegaly, Conn's syndrome or hyperaldosteronism, hyperparathyroidism and pheochromocytoma.[11][31] Other causes of secondary hypertension include obesity, sleep apnea, pregnancy, coarctation of the aorta, excessive liquorice consumption and certain prescription medicines, herbal remedies and illegal drugs.[11][32]

Pathophysiology

Main article: Pathophysiology of hypertension
A diagram explaining factors affecting arterial pressure

In most people with established essential (primary) hypertension, increased resistance to blood flow (total peripheral resistance) accounts for the high pressure and cardiac output is normal.[33] There is evidence that some younger people with prehypertension or 'borderline hypertension' have high cardiac output, an elevated heart rate and normal peripheral resistance, termed hyperkinetic borderline hypertension.[34] These individuals develop the typical features of established essential hypertension in later life as their cardiac output falls and peripheral resistance rises with age.[34] Whether this pattern is typical of all people who ultimately develop hypertension is disputed.[35] The increased peripheral resistance in established hypertension is mainly attributable to structural narrowing of small arteries and arterioles,[36] although a reduction in the number or density of capillaries may also contribute.[37] Hypertension is also associated with decreased peripheral venous compliance[38] which may increase venous return, increase cardiac preload and, ultimately, cause diastolic dysfunction. Whether increased active vasoconstriction plays a role in established essential hypertension is unclear.[39]

Pulse pressure (the difference between systolic and diastolic blood pressure) is frequently increased in older people with hypertension. This can mean that systolic pressure is abnormally high, but diastolic pressure may be normal or low — a condition termed isolated systolic hypertension.[40] The high pulse pressure in elderly people with hypertension or isolated systolic hypertension is explained by increased arterial stiffness, which typically accompanies aging and may be exacerbated by high blood pressure.[41]

Many mechanisms have been proposed to account for the rise in peripheral resistance in hypertension. Most evidence implicates either:

and/or

These mechanisms are not mutually exclusive and it is likely that both contribute to some extent in most cases of essential hypertension. It has also been suggested that endothelial dysfunction and vascular inflammation may also contribute to increased peripheral resistance and vascular damage in hypertension.[44][45]

Diagnosis

Typical tests performed in hypertension
System Tests
Renal Microscopic urinalysis, proteinuria, serum BUN (blood urea nitrogen) and/or creatinine
Endocrine Serum sodium, potassium, calcium, TSH (thyroid-stimulating hormone).
Metabolic Fasting blood glucose, total cholesterol, HDL and LDL cholesterol, triglycerides
Other Hematocrit, electrocardiogram, and chest radiograph
Sources: Harrison's principles of internal medicine[46] others[47][48][49][50][51]

Hypertension is diagnosed on the basis of a persistently high blood pressure. Traditionally,[3] this requires three separate sphygmomanometer measurements at one monthly intervals.[52] Initial assessment of the hypertensive patient should include a complete history and physical examination. With the availability of 24-hour ambulatory blood pressure monitors and home blood pressure machines, the importance of not wrongly diagnosing those who have white coat hypertension has led to a change in protocol advice in the United Kingdom, with best practice of now following up a single raised clinic reading with ambulatory measurement, or less ideally with home blood pressure monitoring over the course of 7 days.[3]

Once the diagnosis of hypertension has been made, physicians will attempt to identify the underlying cause based on risk factors and other symptoms, if present. Secondary hypertension is more common in preadolescent children, with most cases caused by renal disease. Primary or essential hypertension is more common in adolescents and has multiple risk factors, including obesity and a family history of hypertension.[53] Laboratory tests can also be performed to identify possible causes of secondary hypertension, and to determine whether hypertension has caused damage to the heart, eyes, and kidneys. Additional tests for diabetes and high cholesterol levels are usually performed because these conditions are additional risk factors for the development of heart disease and require treatment.[1]

Serum creatinine is measured as a test of renal function, to assess the presence of kidney disease, which can be either the cause or the result of hypertension. Serum creatinine alone may overestimate glomerular filtration rate and recent guidelines advocate the use of predictive equations such as the Modification of Diet in Renal Disease (MDRD) formula to estimate glomerular filtration rate (eGFR).[54] eGFR can also provides a baseline measurement of kidney function that can be used to monitor for side effects of certain antihypertensive drugs on kidney function. Additionally, testing of urine samples for protein is used as a secondary indicator of kidney disease. Glucose testing is done to determine if diabetes mellitus is present. Electrocardiogram (EKG/ECG) testing is done to check for evidence that the heart is under strain from high blood pressure. It may also show whether there is thickening of the heart muscle (left ventricular hypertrophy) or whether the heart has experienced a prior minor disturbance such as a silent heart attack. A chest X-ray or an echocardiogram may also be performed to look for signs of heart enlargement or damage to the heart.[11]

Prevention

Much of the disease burden of high blood pressure is experienced by people who are not hypertensive.[55] Consequently, population strategies are required to reduce the consequences of high blood pressure and reduce the need for antihypertensive drug therapy. Lifestyle changes are recommended to lower blood pressure, before starting drug therapy. The 2004 British Hypertension Society guidelines[55] proposed the following lifestyle changes consistent with those outlined by the US National High BP Education Program in 2002[56] for the primary prevention of hypertension:

  • maintain normal body weight for adults (e.g. body mass index 20–25 kg/m2)
  • reduce dietary sodium intake to <100 mmol/ day (<6 g of sodium chloride or <2.4 g of sodium per day)
  • engage in regular aerobic physical activity such as brisk walking (≥30 min per day, most days of the week)
  • limit alcohol consumption to no more than 3 units/day in men and no more than 2 units/day in women
  • consume a diet rich in fruit and vegetables (e.g. at least five portions per day);
  • consume a diet with reduced content of saturated and total fat.

Effective lifestyle modification may lower blood pressure as much an individual antihypertensive drug. Combinations of two or more lifestyle modifications can achieve even better results.[55]

Treatment

Lifestyle modifications

The first line of treatment for hypertension is identical to the recommended preventive lifestyle changes[57] and includes: dietary changes[58] physical exercise, and weight loss. These have all been shown to significantly reduce blood pressure in people with hypertension.[59] If hypertension is high enough to justify immediate use of medications, lifestyle changes are still recommended in conjunction with medication. Different programs aimed to reduce psychological stress such as biofeedback, relaxation or meditation are advertised to reduce hypertension. However, in general claims of efficacy are not supported by scientific studies, which have been in general of low quality.[60][61][62]

Dietary change such as a low sodium diet is beneficial. A long term (more than 4 weeks) low sodium diet in Caucasians is effective in reducing blood pressure, both in people with hypertension and in people with normal blood pressure.[63] Also, the DASH diet (Dietary Approaches to Stop Hypertension), a diet rich in nuts, whole grains, fish, poultry, fruits and vegetables promoted by the National Heart, Lung, and Blood Institute (part of the NIH, a United States government organization) lowers blood pressure. A major feature of the plan is limiting intake of sodium, although the diet is also rich in potassium, magnesium, calcium, as well as protein.[64]

Medications

Several classes of medications, collectively referred to as antihypertensive drugs, are currently available for treating hypertension. Drug prescription should take into account the patient's absolute cardiovascular risk (including risk of myocardial infarction and stroke) as well as blood pressure readings, in order to gain a more accurate picture of the patient's cardiovascular profile.[65] If drug treatment is initiated the National Heart, Lung, and Blood Institute's Seventh Joint National Committee on High Blood Pressure (JNC-7)[54] recommends that the physician not only monitor for response to treatment but should also assess for any adverse or untoward reaction resulting from the medication(s). Reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34%, of ischaemic heart disease by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease.[66] The aim of treatment should be to reduce blood pressure to <140/90 mmHg for most individuals, and lower for individuals with diabetes or kidney disease (some medical professionals recommend keeping levels below 120/80 mmHg).[67] If the blood pressure goal is not met, a change in treatment should be made as therapeutic inertia is a clear impediment to blood pressure control.[68] Comorbidity also plays a role in determining target blood pressure, with lower BP targets applying to patients with end-organ damage or proteinuria.[65]

Often multiple medications are needed to be combined to achieve the goal blood pressure. Guidelines on the choice of first line agent and how to best to step up treatment with multiple agents for various subgroups of patients have changed over time and differ between countries.

In the UK low dose thiazide-based diuretic were previously thought the best first line agent,[69] but latest guidelines emphasise calcium channel blockers (CCB) in preference for patients over the age of 55 years or if of African or Caribbean family origin, with angiotensin converting enzyme inhibitors (ACE-I) used first line for younger patients.[70] Preferred dual therapy is generally CCB with an ACE-I, and triple therapy with addition of a thiazide-like diuretic. If a fourth agent is needed then spironolactone or a higher-dose of a thiazide-like diuretic can be used. If spironolactone or high dose thiazide are contraindicated, not tolerated or ineffective, other additional agents that may be considered are alpha blockers or beta blockers.[70] Angiotensin II receptor antagonists are suggested as preferable to ACE-I for people of African or Caribbean ethnicity, and are an alternative for patients who are unable to tolerate ACE-I. Beta-blockers may be also be considered in younger people, particularly those with intolerance of, or contraindication to ACE-I and angiotensin II receptor antagonists, or women of child-bearing potential, or people with evidence of increased sympathetic drive.[70]

Drug combinations

The majority of patients require more than one drug to control their hypertension. JNC7[54] and ESH-ESC guidelines[4] advocate starting treatment with two drugs when blood pressure is >20 mmHg above systolic or >10 mmHg above diastolic targets. Preferred combinations are renin–angiotensin system inhibitors and calcium channel blockers, or renin–angiotensin system inhibitors and diuretics.[71] Acceptable combinations include calcium channel blockers and diuretics, beta-blockers and diuretics, dihydropyridine calcium channel blockers and beta-blockers, or dihydropyridine calcium channel blockers with either verapamil or diltiazem. Unacceptable combinations are non-dihydropyridine calcium blockers (such as verapamil or diltiazem) and beta-blockers, dual renin–angiotensin system blockade (e.g. angiotensin converting enzyme inhibitor + angiotensin receptor blocker), renin–angiotensin system blockers and beta-blockers, beta-blockers and anti-adrenergic drugs.[71] Combinations of an ACE-inhibitor or angiotensin II–receptor antagonist, a diuretic and an NSAID (including selective COX-2 inhibitors and non-prescribed drugs such as ibuprofen) should be avoided whenever possible due to a high documented risk of acute renal failure. The combination is known colloquially as a "triple whammy" in the Australian health industry.[57]

Fixed dose combinations

Tablets containing fixed combinations of two classes of drugs are available and whilst convenient for the patient, may be best reserved for patients who have been established on the individual components.[72]

In the elderly

Treating moderate to severe hypertension decreases death rates and cardiovascular morbidity and mortality in people aged 60 and older.[73] There are limited studies of people over 80 years old but a recent meta-analysis that pooled results from several clinical trials concluded that antihypertensive treatment reduced cardiovascular deaths and disease, but did not significantly reduce total death rates.[73] The recommended BP goal is advised as <140/90 mm Hg with thiazide diuretics being the first line medication in America,[74] but in the revised UK guidelines calcium-channel blockers are advocated as first line with targets of clinic readings <150/90, or <145/85 on ambulatory or home blood pressure monitoring.[70]

Resistant hypertension

Resistant hypertension is defined as hypertension that remains above goal blood pressure in spite of concurrent use of three antihypertensive agents belonging to different antihypertensive drug classes. Patients who require four or more drugs to control their blood pressure are also considered to have resistant hypertension. Guidelines for treating resistant hypertension have been published in the UK[75] and US.[76]

Epidemiology

As of 2000, nearly one billion people or ~26% of the adult population of the world had hypertension.[77] It was common in both developed (333 million) and undeveloped (639 million) countries.[77] However rates vary markedly in different regions with rates as low as 3.4% (men) and 6.8% (women) in rural India and as high as 68.9% (men) and 72.5% (women) in Poland.[78]

In 1995 it was estimated that 43 million people in the United States had hypertension or were taking antihypertensive medication, almost 24% of the adult United States population.[79] The prevalence of hypertension in the United States is increasing and reached 29% in 2004.[80][81] It is more common in blacks and native Americans and less in whites and Mexican Americans, rates increase with age, and is greater in the southeastern United States. Hypertension is more prevalent in men (though menopause tends to decrease this difference) and those of low socioeconomic status.[1]

In children

The prevalence of high blood pressure in the young is increasing.[82] Most childhood hypertension, particularly in preadolescents, is secondary to an underlying disorder. Aside from obesity, kidney disease is the most common (60–70%) cause of hypertension in children. Adolescents usually have primary or essential hypertension, which accounts for 85–95% of cases.[83]

History

Image of veins from Harvey's Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus

Modern understanding of the cardiovascular system began with the work of physician William Harvey (1578–1657), who described the circulation of blood in his book "De motu cordis". The English clergyman Stephen Hales made the first published measurement of blood pressure in 1733.[84][85] Descriptions of hypertension as a disease came among others from Thomas Young in 1808 and especially Richard Bright in 1836.[84] The first report of elevated blood pressure in a patient without evidence of kidney disease was made by Frederick Akbar Mahomed (1849–1884).[86] However hypertension as a clinical entity came into being in 1896 with the invention of the cuff-based sphygmomanometer by Scipione Riva-Rocci in 1896.[87] This allowed blood pressure to be measured in the clinic. In 1905, Nikolai Korotkoff improved the technique by describing the Korotkoff sounds that are heard when the artery is ausculated with a stethoscope while the sphygmomanometer cuff is deflated.[85]

The concept of essential hypertension ('hypertonie essential') was introduced in 1925 by the physiologist Otto Frank to describe elevated blood pressure for which no cause could be found. In 1928, the term malignant hypertension was coined by physicians from the Mayo Clinic to describe a syndrome of very high blood pressure, severe retinopathy and adequate kidney function which usually resulted in death within a year from strokes, heart failure or kidney failure.[88] A prominent sufferer of severe hypertension was Franklin D. Roosevelt.[89] However, while the menace of severe or malignant hypertension was well recognised, the risks of more moderate elevations of blood pressure were uncertain and the benefits of treatment doubtful. Consequently, hypertension was often classified into "malignant" and "benign". In 1931, John Hay, Professor of Medicine at Liverpool University, wrote that "there is some truth in the saying that the greatest danger to a man with a high blood pressure lies in its discovery, because then some fool is certain to try and reduce it".[90][91] This view was echoed by the eminent US cardiologist Paul Dudley White in 1937, who suggested that "hypertension may be an important compensatory mechanism which should not be tampered with, even were it certain that we could control it".[92] Charles Friedberg's 1949 classic textbook "Diseases of the Heart",[93] stated that "people with 'mild benign' hypertension ... [defined as blood pressures up to levels of 210/100 mm Hg] ... need not be treated".[91] However the tide of medical opinion was turning: it was increasingly recognised in the 1950s that "benign" hypertension was not harmless.[94] Over the next decade increasing evidence accumulated from actuarial reports[85][95] and longitudinal studies, such as the Framingham Heart Study,[96] that "benign" hypertension increased death and cardiovascular disease, and that these risks increased in a graded manner with increasing blood pressure across the whole spectrum of population blood pressures. Subsequently the National Institutes of Health also sponsored other population studies, which additionally showed that African Americans had a higher burden of hypertension and its complications.[97]

Historically the treatment for what was called the "hard pulse disease" consisted in reducing the quantity of blood by blood letting or the application of leeches.[84] This was advocated by The Yellow Emperor of China, Cornelius Celsus, Galen, and Hipocrates.[84]

In the 19th and 20th centuries, before effective pharmacological treatment for hypertension became possible, three treatment modalities were used, all with numerous side-effects: strict sodium restriction (for example the rice diet[84]), sympathectomy (surgical ablation of parts of the sympathetic nervous system), and pyrogen therapy (injection of substances that caused a fever, indirectly reducing blood pressure).[84][97] The first chemical for hypertension, sodium thiocyanate, was used in 1900 but had many side effects and was unpopular.[84] Several other agents were developed after the Second World War, the most popular and reasonably effective of which were tetramethylammonium chloride and its derivative hexamethonium, hydralazine and reserpine (derived from the medicinal plant Rauwolfia serpentina). A major breakthrough was achieved with the discovery of the first well-tolerated orally available agents. The first was chlorothiazide, the first thiazide diuretic and developed from the antibiotic sulfanilamide, which became available in 1958;[84][98] it increased salt excretion while preventing fluid accumulation. A randomized controlled trial sponsored by the Veterans Administration comparing hydrochlorothiazide plus reserpine plus hydralazine versus placebo had to be stopped early in a high blood pressure group because those not receiving treatment developed many more complications and it was deemed unethical to withhold treatment from them. The study continued in people with lower blood pressures and showed that treatment even in people with mild hypertension more than halved the risk of cardiovascular death.[99] In 1975, the Lasker Special Public Health Award was awarded to the team that developed chlorothiazide.[97] The results of these studies prompted public health campaigns to increase public awareness of hypertension and promoted the measurement and treatment of high blood pressure. These measures appear to have contributed at least in part to the observed 50% fall in stroke and ischemic heart disease between 1972 and 1994.[97]

Soon more drugs became available to treat hypertension. The British physician James W. Black developed beta blockers in the early 1960s;[100] these were initially used for angina, but turned out to lower blood pressure. Black received the 1976 Lasker Award and in 1988 the Nobel Prize in Physiology or Medicine for his discovery.[97] The next class of antihypertensives to be discovered were calcium channel blockers. The first member was verapamil, a derivative of papaverine that was initially thought to be a beta blocker and used for angina, but then turned out to have a different mode of action and was shown to lower blood pressure.[97] The renin-angiotensin system was known to play an important role in blood pressure regulation, and angiotensin converting enzyme (ACE) inhibitors were developed through rational drug design. In 1977 captopril, an orally active agent, was described;[101] this led to the development of a number of other ACE inhibitors.[97] More recently angiotensin receptor blockers and renin inhibitors have also been introduced as antihypertensive agents.[102][103]

Society and culture

Economics

High blood pressure is the most common chronic medical problem prompting visits to primary health care providers in USA. The American Heart Association estimated the direct and indirect costs of high blood pressure in 2010 as $76.6 billion.[104] Hypertension affects ≈76,400,000 US adults (≈34% of the US population) and African American adults have among the highest rates of hypertension in the world (44%).[104] In the US 80% of people with hypertension are aware of their condition, 71% take some antihypertensive medication, but only 48% of people aware that they have hypertension are adequately controlled.[104] Adequate management of hypertension can be hampered by inadequacies in the diagnosis, treatment, and/or control of high blood pressure.[105] Health care providers face many obstacles to achieving blood pressure control, including resistance to taking multiple medications to reach blood pressure goals. Patients also face the challenges of adhering to medicine schedules and making lifestyle changes. Nonetheless, the achievement of blood pressure goals is possible, and most importantly, lowering blood pressure significantly reduces the risk of death due to heart disease and stroke, the development of other debilitating conditions, and the cost associated with advanced medical care.[106][107]

Awareness

Graph showing, prevalence of awareness, treatment and control of hypertension compared between the four studies of NHANES[80]

The World Health Organization has identified hypertension, or high blood pressure, as the leading cause of cardiovascular mortality. The World Hypertension League (WHL), an umbrella organization of 85 national hypertension societies and leagues, recognized that more than 50% of the hypertensive population worldwide are unaware of their condition.[108] To address this problem, the WHL initiated a global awareness campaign on hypertension in 2005 and dedicated May 17 of each year as World Hypertension Day (WHD). Over the past three years, more national societies have been engaging in WHD and have been innovative in their activities to get the message to the public. In 2007, there was record participation from 47 member countries of the WHL. During the week of WHD, all these countries – in partnership with their local governments, professional societies, nongovernmental organizations and private industries – promoted hypertension awareness among the public through several media and public rallies. Using mass media such as Internet and television, the message reached more than 250 million people. As the momentum picks up year after year, the WHL is confident that almost all the estimated 1.5 billion people affected by elevated blood pressure can be reached.[109]

References

  1. ^ a b c d Carretero OA, Oparil S (2000). "Essential hypertension. Part I: definition and etiology". Circulation. 101 (3): 329–35. doi:10.1161/01.CIR.101.3.329. PMID 10645931. {{cite journal}}: Unknown parameter |month= ignored (help)
  2. ^ a b c d Chobanian AV, Bakris GL, Black HR; et al. (2003). "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure". Hypertension. 42 (6): 1206–52. doi:10.1161/01.HYP.0000107251.49515.c2. PMID 14656957. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. ^ a b c National Clinical Guidance Centre (August 2011). "7 Diagnosis of Hypertension, 7.5 Link from evidence to recommendations". Hypertension (NICE CG 127) (PDF). National Institute for Health and Clinical Excellence. p. 102. Retrieved 2011-12-22. Cite error: The named reference "NICE127 full" was defined multiple times with different content (see the help page).
  4. ^ a b c Mancia G, De Backer G, Dominiczak A; et al. (2007). "2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension". J. Hypertens. 25 (9): 1751–62. doi:10.1097/HJH.0b013e3282f0580f. PMID 17762635. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ a b Williams B, Poulter NR, Brown MJ; et al. (2004). "Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV". J Hum Hypertens. 18 (3): 139–85. doi:10.1038/sj.jhh.1001683. PMID 14973512. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ a b c Dionne JM, Abitbol CL, Flynn JT (2012). "Hypertension in infancy: diagnosis, management and outcome". Pediatr. Nephrol. 27 (1): 17–32. doi:10.1007/s00467-010-1755-z. PMID 21258818. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  7. ^ Din-Dzietham R, Liu Y, Bielo MV, Shamsa F (2007). "High blood pressure trends in children and adolescents in national surveys, 1963 to 2002". Circulation. 116 (13): 1488–96. doi:10.1161/CIRCULATIONAHA.106.683243. PMID 17846287. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  8. ^ a b c d "The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents". Pediatrics. 114 (2 Suppl 4th Report): 555–76. 2004. PMID 15286277. {{cite journal}}: Unknown parameter |month= ignored (help)
  9. ^ a b c Fisher ND, Williams GH (2005). "Hypertensive vascular disease". In Kasper DL, Braunwald E, Fauci AS; et al. (eds.). Harrison's Principles of Internal Medicine (16th ed.). New York, NY: McGraw-Hill. pp. 1463–81. ISBN 0-07-139140-1. {{cite book}}: Explicit use of et al. in: |editor= (help)CS1 maint: multiple names: editors list (link)
  10. ^ a b Wong T, Mitchell P (2007). "The eye in hypertension". Lancet. 369 (9559): 425–35. doi:10.1016/S0140-6736(07)60198-6. PMID 17276782. {{cite journal}}: Unknown parameter |month= ignored (help)
  11. ^ a b c d e f g h i j k l m n o p q r s O'Brien, Eoin; Beevers, D. G.; Lip, Gregory Y. H. (2007). ABC of hypertension. London: BMJ Books. ISBN 1-4051-3061-X.{{cite book}}: CS1 maint: multiple names: authors list (link)
  12. ^ a b c d e Marik PE, Varon J (2007). "Hypertensive crises: challenges and management". Chest. 131 (6): 1949–62. doi:10.1378/chest.06-2490. PMID 17565029. {{cite journal}}: Unknown parameter |month= ignored (help)
  13. ^ Gibson, Paul (July 30, 2009). "Hypertension and Pregnancy". eMedicine Obstetrics and Gynecology. Medscape. Retrieved 2009-06-16. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  14. ^ a b Rodriguez-Cruz, Edwin (April 6, 2010). "Hypertension". eMedicine Pediatrics: Cardiac Disease and Critical Care Medicine. Medscape. Retrieved 2009-06-16. {{cite web}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  15. ^ World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009
  16. ^ Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002). "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies". Lancet. 360 (9349): 1903–13. doi:10.1016/S0140-6736(02)11911-8. PMID 12493255. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  17. ^ Singer DR, Kite A (2008). "Management of hypertension in peripheral arterial disease: does the choice of drugs matter?". European Journal of Vascular and Endovascular Surgery. 35 (6): 701–8. doi:10.1016/j.ejvs.2008.01.007. PMID 18375152. {{cite journal}}: Unknown parameter |month= ignored (help)
  18. ^ Zeng C, Villar VA, Yu P, Zhou L, Jose PA (2009). "Reactive oxygen species and dopamine receptor function in essential hypertension". Clinical and Experimental Hypertension. 31 (2): 156–78. doi:10.1080/10641960802621283. PMID 19330604. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  19. ^ Chen X, Wen W, Anstey KJ, Sachdev PS (2009). "Prevalence, incidence, and risk factors of lacunar infarcts in a community sample". Neurology. 73 (4): 266–72. doi:10.1212/WNL.0b013e3181aa52ea. PMID 19636046. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  20. ^ Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002 Feb 27;287(8):1003–10.
  21. ^ The International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478: 103–109 doi:10.1038/nature10405
  22. ^ Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001;104:545-56.
  23. ^ He FJ, MacGregor GA.A comprehensive review on salt and health and current experience of worldwide salt reduction programmes.J Hum Hypertens. 2009 Jun;23(6):363-84.
  24. ^ a b Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, Williams B, Ford GA.Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials.J Hypertens. 2006;24:215-33.
  25. ^ Haslam DW, James WP (2005). "Obesity". Lancet. 366 (9492): 1197–209. doi:10.1016/S0140-6736(05)67483-1. PMID 16198769.
  26. ^ Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA; et al. (2002). "Primary prevention of hypertension:Clinical and public health advisory from The National High Blood Pressure Education Program". JAMA. 288 (15): 1882–8. doi:10.1001/jama.288.15.1882. PMID 12377087. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  27. ^ Mesas AE, Leon-Muñoz LM, Rodriguez-Artalejo F, Lopez-Garcia E. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. Am J Clin Nutr. 2011;94:1113–26.
  28. ^ Vaidya A, Forman JP (2010). "Vitamin D and hypertension: current evidence and future directions". Hypertension. 56 (5): 774–9. doi:10.1161/HYPERTENSIONAHA.109.140160. PMID 20937970. {{cite journal}}: Unknown parameter |month= ignored (help)
  29. ^ Sorof J, Daniels S (2002). "Obesity hypertension in children: a problem of epidemic proportions". Hypertension. 40 (4): 441–447. doi:10.1161/01.HYP.0000032940.33466.12. PMID 12364344. Retrieved 2009-06-03. {{cite journal}}: Unknown parameter |month= ignored (help)
  30. ^ a b Lawlor DA, Smith GD. Early life determinants of adult blood pressure. Curr Opin Nephrol Hypertens. 2005 May;14(3):259-64.
  31. ^ Dluhy RG, Williams GH. Endocrine hypertension. In: Wilson JD, Foster DW, Kronenberg HM, eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa: WB Saunders; 1998:729-49.
  32. ^ Grossman E, Messerli FH (2012). "Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension". Am. J. Med. 125 (1): 14–22. doi:10.1016/j.amjmed.2011.05.024. PMID 22195528. {{cite journal}}: Unknown parameter |month= ignored (help)
  33. ^ Conway J (1984). "Hemodynamic aspects of essential hypertension in humans". Physiol. Rev. 64 (2): 617–60. PMID 6369352. {{cite journal}}: Unknown parameter |month= ignored (help)
  34. ^ a b Palatini P, Julius S (2009). "The role of cardiac autonomic function in hypertension and cardiovascular disease". Curr. Hypertens. Rep. 11 (3): 199–205. PMID 19442329. {{cite journal}}: Unknown parameter |month= ignored (help)
  35. ^ Andersson OK, Lingman M, Himmelmann A, Sivertsson R, Widgren BR (2004). "Prediction of future hypertension by casual blood pressure or invasive hemodynamics? A 30-year follow-up study". Blood Press. 13 (6): 350–4. PMID 15771219.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  36. ^ Folkow B (1982). "Physiological aspects of primary hypertension". Physiol. Rev. 62 (2): 347–504. PMID 6461865. {{cite journal}}: Unknown parameter |month= ignored (help)
  37. ^ Struijker Boudier HA, le Noble JL, Messing MW, Huijberts MS, le Noble FA, van Essen H (1992). "The microcirculation and hypertension". J Hypertens Suppl. 10 (7): S147–56. PMID 1291649. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  38. ^ Safar ME, London GM (1987). "Arterial and venous compliance in sustained essential hypertension". Hypertension. 10 (2): 133–9. PMID 3301662. {{cite journal}}: Unknown parameter |month= ignored (help)
  39. ^ Schiffrin EL (1992). "Reactivity of small blood vessels in hypertension: relation with structural changes. State of the art lecture". Hypertension. 19 (2 Suppl): II1–9. PMID 1735561. {{cite journal}}: Unknown parameter |month= ignored (help)
  40. ^ Chobanian AV (2007). "Clinical practice. Isolated systolic hypertension in the elderly". N. Engl. J. Med. 357 (8): 789–96. doi:10.1056/NEJMcp071137. PMID 17715411. {{cite journal}}: Unknown parameter |month= ignored (help)
  41. ^ Zieman SJ, Melenovsky V, Kass DA (2005). "Mechanisms, pathophysiology, and therapy of arterial stiffness". Arterioscler. Thromb. Vasc. Biol. 25 (5): 932–43. doi:10.1161/01.ATV.0000160548.78317.29. PMID 15731494. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  42. ^ Navar LG (2010). "Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension". J. Appl. Physiol. 109 (6): 1998–2000, discussion 2015. doi:10.1152/japplphysiol.00182.2010a. PMC 3006411. PMID 21148349. {{cite journal}}: Unknown parameter |month= ignored (help)
  43. ^ Esler M, Lambert E, Schlaich M (2010). "Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension". J. Appl. Physiol. 109 (6): 1996–8, discussion 2016. doi:10.1152/japplphysiol.00182.2010. PMID 20185633. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  44. ^ Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S (2009). "Endothelium-dependent contractions and endothelial dysfunction in human hypertension". Br. J. Pharmacol. 157 (4): 527–36. doi:10.1111/j.1476-5381.2009.00240.x. PMC 2707964. PMID 19630832. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  45. ^ Marchesi C, Paradis P, Schiffrin EL (2008). "Role of the renin-angiotensin system in vascular inflammation". Trends Pharmacol. Sci. 29 (7): 367–74. doi:10.1016/j.tips.2008.05.003. PMID 18579222. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  46. ^ Loscalzo, Joseph; Fauci, Anthony S.; Braunwald, Eugene; Dennis L. Kasper; Hauser, Stephen L; Longo, Dan L. (2008). Harrison's principles of internal medicine. McGraw-Hill Medical. ISBN 0-07-147691-1.{{cite book}}: CS1 maint: multiple names: authors list (link)
  47. ^ Padwal RS; Hemmelgarn BR; Khan NA; et al. (2009). "The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk". Canadian Journal of Cardiology. 25 (5): 279–86. doi:10.1016/S0828-282X(09)70491-X. PMC 2707176. PMID 19417858. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  48. ^ Padwal RJ; Hemmelgarn BR; Khan NA; et al. (2008). "The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk". Canadian Journal of Cardiology. 24 (6): 455–63. doi:10.1016/S0828-282X(08)70619-6. PMC 2643189. PMID 18548142. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  49. ^ Padwal RS; Hemmelgarn BR; McAlister FA; et al. (2007). "The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk". Canadian Journal of Cardiology. 23 (7): 529–38. doi:10.1016/S0828-282X(07)70797-3. PMC 2650756. PMID 17534459. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  50. ^ Hemmelgarn BR; McAlister FA; Grover S; et al. (2006). "The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – Blood pressure measurement, diagnosis and assessment of risk". Canadian Journal of Cardiology. 22 (7): 573–81. doi:10.1016/S0828-282X(06)70279-3. PMC 2560864. PMID 16755312. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  51. ^ Hemmelgarn BR; McAllister FA; Myers MG; et al. (2005). "The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk". Canadian Journal of Cardiology. 21 (8): 645–56. PMID 16003448. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  52. ^ North of England Hypertension Guideline Development Group (1 August 2004). "Frequency of measurements". Essential hypertension (NICE CG18). National Institute for Health and Clinical Excellence. p. 53. Retrieved 2011-12-22.
  53. ^ Luma GB, Spiotta RT (2006). "Hypertension in children and adolescents". Am Fam Physician. 73 (9): 1558–68. PMID 16719248. {{cite journal}}: Unknown parameter |month= ignored (help)
  54. ^ a b c Chobanian AV, Bakris GL, Black HR; et al. (2003). "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure". Hypertension. 42 (6): 1206–52. doi:10.1161/01.HYP.0000107251.49515.c2. PMID 14656957. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  55. ^ a b c Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JP, Sever PS and Thom S McG; The BHS Guidelines Working Party Guidelines for Management of Hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004 - BHS IV. Journal of Human Hypertension 2004; 18: 139-185.
  56. ^ Whelton PK; et al. (2002). "Primary prevention of hypertension. Clinical and public health advisory from the National High Blood Pressure Education Program". JAMA. 288 (15): 1882–1888. doi:10.1001/jama.288.15.1882. PMID 12377087. {{cite journal}}: Explicit use of et al. in: |author= (help)
  57. ^ a b "NPS Prescribing Practice Review 52: Treating hypertension". NPS Medicines Wise. September 1, 2010. Retrieved November 5, 2010.
  58. ^ Siebenhofer, A (2011-09-07). Siebenhofer, Andrea (ed.). "Long-term effects of weight-reducing diets in hypertensive patients". Cochrane database of systematic reviews (Online). 9: CD008274. doi:10.1002/14651858.CD008274.pub2. PMID 21901719. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  59. ^ Blumenthal JA; Babyak MA; Hinderliter A; et al. (2010). "Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study". Arch. Intern. Med. 170 (2): 126–35. doi:10.1001/archinternmed.2009.470. PMID 20101007. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  60. ^ Greenhalgh J, Dickson R, Dundar Y (2009). "The effects of biofeedback for the treatment of essential hypertension: a systematic review". Health Technol Assess. 13 (46): 1–104. doi:10.3310/hta13460. PMID 19822104. {{cite journal}}: Unknown parameter |doi_brokendate= ignored (|doi-broken-date= suggested) (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  61. ^ Rainforth MV, Schneider RH, Nidich SI, Gaylord-King C, Salerno JW, Anderson JW (2007). "Stress Reduction Programs in Patients with Elevated Blood Pressure: A Systematic Review and Meta-analysis". Curr. Hypertens. Rep. 9 (6): 520–8. doi:10.1007/s11906-007-0094-3. PMC 2268875. PMID 18350109. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  62. ^ Ospina MB; Bond K; Karkhaneh M; et al. (2007). "Meditation practices for health: state of the research". Evid Rep Technol Assess (Full Rep) (155): 1–263. PMID 17764203. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  63. ^ He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004937. DOI: 10.1002/14651858.CD004937.
  64. ^ "Your Guide To Lowering Your Blood Pressure With DASH" (PDF). Retrieved 2009-06-08.
  65. ^ a b Nelson, Mark. "Drug treatment of elevated blood pressure". Australian Prescriber (33): 108–112. Retrieved August 11, 2010.
  66. ^ Law M, Wald N, Morris J (2003). "Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy" (PDF). Health Technol Assess. 7 (31): 1–94. PMID 14604498.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  67. ^ Shaw, Gina (2009-03-07). "Prehypertension: Early-stage High Blood Pressure". WebMD. Retrieved 2009-07-03.
  68. ^ Eni C. Okonofua; Kit N. Simpson; Ammar Jesri; Shakaib U. Rehman; Valerie L. Durkalski; Brent M. Egan (January 23, 2006). "Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control Goals". Hypertension. 47 (2006, 47:345): 345–51. doi:10.1161/01.HYP.0000200702.76436.4b. PMID 16432045. Retrieved 2009-11-22.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  69. ^ Wright JM, Musini VM (2009). Wright, James M (ed.). "First-line drugs for hypertension". Cochrane Database Syst Rev (3): CD001841. doi:10.1002/14651858.CD001841.pub2. PMID 19588327.
  70. ^ a b c d National Institute Clinical Excellence (August 2011). "1.5 Initiating and monitoring antihypertensive drug treatment, including blood pressure targets". GC127 Hypertension: Clinical management of primary hypertension in adults. Retrieved 2011-12-23.
  71. ^ a b Sever PS, Messerli FH (2011). "Hypertension management 2011: optimal combination therapy". Eur. Heart J. 32 (20): 2499–506. doi:10.1093/eurheartj/ehr177. PMID 21697169. {{cite journal}}: Unknown parameter |month= ignored (help)
  72. ^ "2.5.5.1 Angiotensin-converting enzyme inhibitors". British National Formulary. Vol. No. 62. September 2011. {{cite book}}: |access-date= requires |url= (help); |volume= has extra text (help); External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
  73. ^ a b Musini VM, Tejani AM, Bassett K, Wright JM (2009). Musini, Vijaya M (ed.). "Pharmacotherapy for hypertension in the elderly". Cochrane Database Syst Rev (4): CD000028. doi:10.1002/14651858.CD000028.pub2. PMID 19821263.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  74. ^ Aronow WS, Fleg JL, Pepine CJ; et al. (2011). "ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension". J. Am. Coll. Cardiol. 57 (20): 2037–114. doi:10.1016/j.jacc.2011.01.008. PMID 21524875. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  75. ^ "CG34 Hypertension - quick reference guide" (PDF). National Institute for Health and Clinical Excellence. 28 June 2006. Retrieved 2009-03-04.
  76. ^ Calhoun DA; Jones D; Textor S; et al. (2008). "Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research". Hypertension. 51 (6): 1403–19. doi:10.1161/HYPERTENSIONAHA.108.189141. PMID 18391085. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  77. ^ a b Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005). "Global burden of hypertension: analysis of worldwide data". Lancet. 365 (9455): 217–23. doi:10.1016/S0140-6736(05)17741-1. PMID 15652604.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  78. ^ Kearney PM, Whelton M, Reynolds K, Whelton PK, He J (2004). "Worldwide prevalence of hypertension: a systematic review". J. Hypertens. 22 (1): 11–9. PMID 15106785. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  79. ^ Burt VL; Whelton P; Roccella EJ; et al. (1995). "Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991". Hypertension. 25 (3): 305–13. PMID 7875754. Retrieved 2009-06-05. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  80. ^ a b Burt VL; Cutler JA; Higgins M; et al. (1995). "Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991". Hypertension. 26 (1): 60–9. PMID 7607734. Retrieved 2009-06-05. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  81. ^ Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S (2007). "Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004". Journal of the American Geriatrics Society. 55 (7): 1056–65. doi:10.1111/j.1532-5415.2007.01215.x. PMID 17608879. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  82. ^ Falkner B (2009). "Hypertension in children and adolescents: epidemiology and natural history". Pediatr. Nephrol. 25 (7): 1219–24. doi:10.1007/s00467-009-1200-3. PMC 2874036. PMID 19421783. {{cite journal}}: Unknown parameter |month= ignored (help)
  83. ^ Luma GB, Spiotta RT (2006). "Hypertension in children and adolescents". Am Fam Physician. 73 (9): 1558–68. PMID 16719248. {{cite journal}}: Unknown parameter |month= ignored (help)
  84. ^ a b c d e f g h Esunge PM (1991). "From blood pressure to hypertension: the history of research". J R Soc Med. 84 (10): 621. PMC 1295564. PMID 1744849. {{cite journal}}: Unknown parameter |month= ignored (help)
  85. ^ a b c Kotchen TA (2011). "Historical trends and milestones in hypertension research: a model of the process of translational research". Hypertension. 58 (4): 522–38. doi:10.1161/HYPERTENSIONAHA.111.177766. PMID 21859967. {{cite journal}}: Unknown parameter |month= ignored (help)
  86. ^ Swales JD, ed. (1995). Manual of hypertension. Oxford: Blackwell Science. pp. xiii. ISBN 0-86542-861-1.
  87. ^ Postel-Vinay N, ed. (1996). A century of arterial hypertension 1896–1996. Chichester: Wiley. p. 213. ISBN 0-471-96788-2.
  88. ^ Keith NM, Wagener HP, Kernohan JW (1928). "The syndrome of malignant hypertension". Arch. Intern. Med. 41 (2): 141–188. doi:10.1001/archinte.1928.00130140003001.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  89. ^ Bruenn HG (1970). "Clinical notes on the illness and death of president Franklin D. Roosevelt". Ann. Int. Med. 72 (4): 579–591. PMID 4908628.
  90. ^ Hay JH (1931). "A British Medical Association Lecture on THE SIGNIFICANCE OF A RAISED BLOOD PRESSURE". Br. Med. J. 2 (3679): 43–47. doi:10.1136/bmj.2.3679.43. PMC 2314188. PMID 20776269.
  91. ^ a b Moser M (2006). "Historical perspectives on the management of hypertension". J. Clin. Hypertens. (Greenwich). 8 (8 Suppl 2): 15–20, quiz 39. doi:10.1111/j.1524-6175.2006.05836.x. PMID 16894244. {{cite journal}}: Unknown parameter |month= ignored (help)
  92. ^ White PD (1937). Heart Disease (2nd ed.). New York, NY: MacMillan Co. p. 326.
  93. ^ Friedberg CK (1949). Diseases of the Heart. Philadelphia, PA: WB Saunders Co.
  94. ^ Pickering GW (1952). "The natural history of hypertension". Br. Med. Bull. 8 (4): 305–9. PMID 12987687.
  95. ^ Society of Actuaries Committee on Mortality (1960). Build and blood pressure study, 1959. Chicago, IL: Society of Actuaries.
  96. ^ "Section 30: Some characteristics related to the incidence of cardiovascular disease and death: 18 year follow-up". The Framingham Study; DHEW Publication No. (NIH) 74-599. Bethesda, MD: National Heart and Lung Institute. 1974.
  97. ^ a b c d e f g Dustan HP, Roccella EJ, Garrison HH (1996). "Controlling hypertension. A research success story". Arch. Intern. Med. 156 (17): 1926–35. doi:10.1001/archinte.156.17.1926. PMID 8823146. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  98. ^ Novello FC, Sprague JM (1957). "Benzothiadiazine dioxides as novel diuretics". J. Am. Chem. Soc. 79 (8): 2028. doi:10.1021/ja01565a079.
  99. ^ Freis ED (1974). "The Veterans Administration Cooperative Study on Antihypertensive Agents. Implications for Stroke Prevention" (PDF). Stroke. 5 (1): 76–77. doi:10.1161/01.STR.5.1.76. PMID 4811316.
  100. ^ Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC (1964). "A new adrenergic beta receptor antagonist". Lancet. 1 (7342): 1080–1. doi:10.1016/S0140-6736(64)91275-9. PMID 14132613. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  101. ^ Ondetti MA, Rubin B, Cushman DW (1977). "Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents". Science. 196 (4288): 441–4. doi:10.1126/science.191908. PMID 191908. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  102. ^ Wexler RR, Greenlee WJ, Irvin JD; et al. (1996). "Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy". J. Med. Chem. 39 (3): 625–56. doi:10.1021/jm9504722. PMID 8576904. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  103. ^ Jensen C, Herold P, Brunner HR (2008). "Aliskiren: the first renin inhibitor for clinical treatment". Nat Rev Drug Discov. 7 (5): 399–410. doi:10.1038/nrd2550. PMID 18340340. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  104. ^ a b c Lloyd-Jones D, Adams RJ, Brown TM; et al. (2010). "Heart disease and stroke statistics--2010 update: a report from the American Heart Association". Circulation. 121 (7): e46–e215. doi:10.1161/CIRCULATIONAHA.109.192667. PMID 20019324. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  105. ^ Alcocer L, Cueto L (2008). "Hypertension, a health economics perspective". Therapeutic Advances in Cardiovascular Disease. 2 (3): 147–55. doi:10.1177/1753944708090572. PMID 19124418. Retrieved 2009-06-20. {{cite journal}}: Unknown parameter |month= ignored (help)
  106. ^ William J. Elliott (2003). "The Economic Impact of Hypertension". The Journal of Clinical Hypertension. 5 (4): 3–13. doi:10.1111/j.1524-6175.2003.02463.x. PMID 12826765. {{cite journal}}: Unknown parameter |month= ignored (help)
  107. ^ Coca A (2008). "Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers)". Clinical Drug Investigation. 28 (4): 211–20. doi:10.2165/00044011-200828040-00002. PMID 18345711.
  108. ^ Chockalingam A (2007). "Impact of World Hypertension Day". Canadian Journal of Cardiology. 23 (7): 517–9. doi:10.1016/S0828-282X(07)70795-X. PMC 2650754. PMID 17534457. {{cite journal}}: Unknown parameter |month= ignored (help)
  109. ^ Chockalingam A (2008). "World Hypertension Day and global awareness". Canadian Journal of Cardiology. 24 (6): 441–4. doi:10.1016/S0828-282X(08)70617-2. PMC 2643187. PMID 18548140. {{cite journal}}: Unknown parameter |month= ignored (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hypertension&oldid=480830820"